Fora Capital, LLC Biomarin Pharmaceutical Inc Transaction History

Fora Capital, LLC

$789 Million
Q3 2024

A detailed history of Fora Capital, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Fora Capital, LLC holds 25,399 shares of BMRN stock, worth $1.69 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

25,399

Previous 8,473 199.76%

Holding current value

$1.69 Million

Previous $697,000 156.1%

% of portfolio

0.23%

Previous 0.09%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$69.02 - $93.84 $1.17 Million - $1.59 Million	16,926 Added 199.76%	25,399 $1.79 Million
Q2 2024 Aug 13, 2024	SELL	$74.43 - $92.22 $1.44 Million - $1.78 Million	-19,350 Reduced 69.55%	8,473 $697,000
Q1 2024 May 02, 2024	BUY	$83.81 - $99.0 $487,941 - $576,378	5,822 Added 26.46%	27,823 $2.43 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $1.68 Million - $2.17 Million	22,001 New	22,001 $2.12 Million
Q4 2022 Feb 08, 2023	SELL	$80.93 - $108.63 $68,547 - $92,009	-847 Reduced 9.97%	7,648 $791,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $697,949 - $823,505	8,495 New	8,495 $720,000
Q1 2022 May 12, 2022	SELL	$74.28 - $92.69 $291,177 - $363,344	-3,920 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $281,142 - $358,562	3,920 New	3,920 $346,000
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $1.2 Million - $1.37 Million	-16,030 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $1.21 Million - $1.36 Million	16,030 New	16,030 $1.34 Billion
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $939,087 - $1.47 Million	-11,805 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $842,522 - $1.14 Million	11,805 New	11,805 $997,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fora Capital, LLC with notifications on news.

Account